arthrex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of arthrex

Property Description
Active ingredient Diclofenac (INN)
Form Oral Tablets (often enteric-coated)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Arthrex (Diclofenac)?

Arthrex refers to a medication based on the active ingredient Diclofenac, which is broadly classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), placing it within the group of Anti-inflammatory Analgesic Agents. This means the drug is fundamentally designed to counteract the biological processes that cause pain and inflammation in the body. Diclofenac is a synthetic compound that is chemically distinguished as a phenylacetic acid derivative. The medication is prepared for oral intake, typically as an enteric-coated tablet, a formulation designed to protect the active substance and facilitate proper systemic absorption.

Composition, Form, and General Purpose

The core composition includes the active ingredient Diclofenac combined with the necessary pharmaceutical vehicle to form the oral tablets. Diclofenac's action involves a potent effect on the cyclooxygenase (COX) enzyme system, a key element in the body’s inflammatory response pathway. The unique advantage of Diclofenac is that its inhibitory action on the COX enzyme is reversible, setting it apart from older, irreversible agents. The general purpose of this medication is to provide relief from discomfort associated with inflammatory conditions, such as chronic joint stiffness, by acting as a dual-action agent to diminish pain signal transmission and actively reduce the underlying inflammation.

Regulatory References

  1. Diclofenac (DailyMed / NIH)

What side effects are possible with arthrex?

Possible Side Effects and Safety Information

The official safety information for Arthrex, based on the active ingredient Diclofenac, describes a risk profile focused on systemic and organ-specific adverse reactions, categorized by frequency and system involvement.

Key Safety Domains and Organ Systems

Regulatory documents emphasize the potential for serious adverse reactions primarily affecting the Cardiovascular and Gastrointestinal Systems. These risks include fatal thrombotic events, such as myocardial infarction (heart attack) and stroke, and serious gastrointestinal events like bleeding, ulceration, and perforation of the stomach or intestines. The official labeling also documents potential effects on the Hepato-biliary System (serious liver injury) and the Renal System (renal papillary necrosis and fluid retention).

Common adverse reactions, observed with higher incidence, frequently involve the Gastrointestinal System (e.g., nausea, abdominal pain, dyspepsia) and the Nervous System (e.g., headache, dizziness), as categorized in official documents.

Time-Related Risk and Population-Specific Statements

Safety statements indicate that the risk of serious cardiovascular events may increase with the duration of use and may occur early in treatment. Gastrointestinal adverse events may manifest at any time during therapy. Official safety texts define specific population risks, noting that older adults have a greater risk for serious gastrointestinal adverse events compared to younger adults.

Regulatory Limitations

Specific usage constraints are documented in official prescribing information. The medication is generally contraindicated in patients with established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, or cerebrovascular disease. It is also prohibited for use in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Arthrex (Diclofenac) is documented in official regulatory sources to typically present with common, but potentially serious, clinical signs. Documented manifestations involve the gastrointestinal system, including nausea, vomiting, and epigastric pain. Effects on the central nervous system may manifest as lethargy, drowsiness, confusion, and general hypotonia. Severe, life-threatening outcomes reported in regulatory documents include gastrointestinal bleeding, acute renal failure, respiratory depression, and coma. Anaphylactoid reactions are also noted as a potential severe complication.


Required Emergency Actions

Individuals must seek immediate medical attention and contact a poison control center immediately, as mandated by regulatory guidance, when an overdose is suspected. Management is based on the official statement that no specific antidotes are known to be available for Diclofenac overdose. Consequently, treatment is restricted to providing symptomatic and supportive care.

For a large overdosage, which is officially defined as an ingestion of 5 to 10 times the recommended dosage, specific decontamination procedures such as gastric lavage and activated charcoal may be considered. Regulatory information notes that forced diuresis or hemodialysis procedures are not useful due to the drug’s significant protein binding.

Therapeutic Uses of arthrex

What Arthrex Treats: Main Uses and Benefits

Managing Chronic Joint and Spinal Inflammation

Arthrex is commonly used in conditions presenting with systemic or localized discomfort that leads to chronic symptoms, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The medication is applied across domains where additional symptomatic support is needed. It plays a role in managing symptoms that may become more disruptive during flare-ups, providing support that helps ease the overall symptom load of joint pain, stiffness, and swelling to contribute to improved day-to-day comfort.

Relief for Acute Musculoskeletal and Traumatic Pain

This medication is considered relevant in clinical settings that involve acute or unstable symptom patterns from acute causes, including post-traumatic injury and postoperative discomfort, as well as localized soft tissue inflammation like tendinitis or bursitis. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and may assist with managing symptoms that create noticeable functional strain or discomfort.

Easing Episodic High-Intensity Pain

Arthrex is applied in scenarios where additional management of discomfort is required during recurrent, sudden, and intense episodes. This includes the treatment of acute, severe pain manifestations like primary dysmenorrhea (menstrual cramps) and the onset of migraine attacks. It is relevant for easing these symptoms, and may assist with maintaining functional stability when symptoms are more noticeable.


Common Indications: Arthrex is used for managing symptomatic discomfort associated with inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal pain, post-operative pain, primary dysmenorrhea, and acute migraine attacks.

“The primary goal is to provide supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

Quick Fact: Relief for Inflammatory Symptoms Arthrex supports the management of multiple symptoms linked to inflammatory or irritative states, including pain, swelling, and stiffness, which collectively interfere with daily functioning.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Arthrex Products

Arthrex products are medical devices (such as screws, anchors, and implants) cleared by the US Food and Drug Administration (FDA) for use in specific surgical procedures, not traditional drug substances. Regulatory eligibility is therefore based on the surgical context rather than specific patient physiological states like age or organ impairment.

Official Regulatory Eligibility Information

Eligibility Scope Regulatory Statement (FDA)
Populations Allowed Patients undergoing surgery in a specific anatomical location (e.g., knee, shoulder, ankle, foot) where the device has a cleared indication for use, such as soft tissue or ligament fixation to bone. Use is designated as Prescription Use.
Use is Restricted To Procedures where the patient's joint is anatomically and structurally suited to receive the selected implant, and where the appropriate supporting tissue function is present (e.g., a functional deltoid muscle for some shoulder systems).
Populations Contraindicated Not explicitly defined in the medical device clearances in terms of patient physiological states (e.g., hepatic impairment, pregnancy, lactation, or general age groups). Contraindications are typically procedure- or material-specific. For example, some devices are not recommended for patients who lack a suspected material sensitivity to specific alloys.
Age-Related Rules Eligibility is generally determined by whether the implant size is patient-appropriate. Some clearances explicitly include adolescent patients (e.g., 12–21 years) for certain fixation devices.

Eligibility for an Arthrex device is ultimately determined by a qualified healthcare professional who assesses the specific surgical need and the patient's suitability for the cleared procedure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Arthrex (Diclofenac) has officially documented interactions that fall into three main regulatory classes: contraindicated combinations, pharmacokinetic alterations, and pharmacodynamic risks.

Interaction Classifications

Classification Constraint / Affected Areas
Contraindicated Combinations Prohibited for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, during the last trimester of pregnancy, and in patients with established cardiovascular disease (e.g., NYHA Class II–IV).
Pharmacodynamic Risks Concurrent use with other systemic NSAIDs, Anticoagulants (e.g., Warfarin), Antiplatelet agents, SSRIs, or Systemic Corticosteroids is associated with an increased risk of serious gastrointestinal bleeding and ulceration.
Exposure Alterations Co-administration with strong CYP2C9 inhibitors (e.g., Voriconazole) can significantly increase the plasma concentrations (AUC and Cmax) of Diclofenac. Diclofenac also increases the plasma concentrations of medicines like Lithium and Methotrexate due to reduced renal clearance.

Population and Substance-Specific Notes

Arthrex use with Diuretics, ACE Inhibitors, or ARBs may lead to a reduced antihypertensive effect and an increased risk of renal function deterioration. Elderly patients are recognized as being at a greater risk for fatal GI events when taking this medication. The official labeling notes that alcohol may increase the risk of gastrointestinal bleeding.

Mechanism of Action

How Arthrex Systems Work

Mechanical Fixation and Stability

This mechanism operates by engaging osseous and soft tissue targets through specialized implants, acting as a direct physical input to the healing process. The systems establish a mechanically secure construct by applying controlled, opposing forces to modulate localized tissue strain. This targeted intervention influences the stability of mechanical signaling at the repair site, a critical step in initiating the physiological repair phase.


Pathway Modulation for Tissue Integration

System components influence local cellular and matrix remodeling pathways. Bio-resorbable materials serve as temporary scaffolds that interact with the surrounding biological environment, engaging mechanisms that affect the signaling dynamics associated with tissue regeneration. This activity supports the regulation of physiological responses at the tissue-to-bone interface, which facilitates the formation and organization of the biological attachment.


Regulating Mechanotransduction Cascades

Surgical adjustment of repair tension acts as a precise input into the mechanotransduction pathway—the process by which cells convert physical load into biochemical signals. This influence modifies the early molecular steps of the signaling sequence. Mechanical engagement results in the limitation of downstream effects of excessive strain, resulting in physiological adjustments that influence the local environment for subsequent tissue repair.

Dosage and Administration Information

How to Use Arthrex (Diclofenac) Oral Tablets

Arthrex, which contains the active ingredient diclofenac, is administered strictly via the oral route using specific dosage forms, such as delayed-release (DR) or extended-release (ER) tablets.


Dosing and Frequency Principles

Official prescribing information establishes that treatment should utilize the lowest effective dose for the shortest duration necessary. The dosing schedule is dependent on both the formulation and the condition being managed:

  • Delayed-Release (DR) Tablets: The total daily dose is typically divided and administered multiple times a day. For instance, in osteoarthritis, the typical total daily range is 100 mg to 150 mg in divided doses, while rheumatoid arthritis may use up to 200 mg daily.
  • Extended-Release (ER) Tablets: These are typically administered once daily, often at a 100 mg strength. The dose should not exceed the maximum daily limit specified on the product label.

Administration Requirements

Diclofenac oral tablets must be swallowed whole with a liquid and should not be crushed, split, or chewed. This requirement is critical to maintaining the tablet’s specific release profile, especially for delayed-release and extended-release forms.

Tablets may be taken with or without food; however, administration alongside food may delay the rate at which the active substance is absorbed. The need for long-term treatment of chronic conditions, such as arthritis, must be periodically re-evaluated. While no general dose change is usually required for older adults or those with mild renal issues, the use of the lowest effective dose remains a key principle in these populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Arthrex (Diclofenac)

This section provides a factual overview of the clinical evaluation of oral diclofenac, based strictly on reports from authoritative governmental sources and peer-reviewed scientific literature. It describes the scope and types of studies conducted for each approved use, focusing on what was studied and what still remains uncertain, without providing any medical guidance.

Evidence for Use in Chronic Joint Conditions (Osteoarthritis, RA, AS)

Research for chronic joint conditions involves conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). For OA, studies are used in research exploring how symptoms change over time, where outcomes related to physical discomfort and daily functioning were measured. Findings describe patterns observed in the studies regarding how outcomes related to physical discomfort were reported. For RA and AS, research examined disease activity scores and functional indices. While research describes short-term symptom patterns, evidence provides limited insight into long-term structural outcomes or disease modification.

Evidence for Use in Acute Pain and Episodic Conditions

Research related to acute pain, such as post-operative discomfort, musculoskeletal injury, primary dysmenorrhea, and acute migraine attacks, relies on single-dose randomized controlled trials (RCTs) and meta-analyses. In acute pain scenarios, studies monitored outcomes describing episodic or acute changes, such as the time it took for changes in physical discomfort to be reported. Findings describe patterns observed in the studies related to how physical discomfort was reported in the immediate short-term. For episodic conditions, research explored patient-reported outcomes describing perceived discomfort during acute episodes, and describes the frequency with which participants reported an outcome of "pain-free" status within the first few hours.

What is Still Uncertain About Arthrex

Official reviews and peer-reviewed scientific literature describe several areas where the evidence base is incomplete or where certainty remains low. One primary limitation is that comparative evidence is lacking to fully contextualize outcomes against all other available NSAID treatments across every approved indication and patient subgroup. Furthermore, the short-term focus of efficacy trials means there is limited information for long-term outcomes, particularly regarding the durability of symptomatic patterns.

Frequently Asked Questions (FAQ)

Common questions about arthrex (FAQ)


Q: How quickly can I expect to notice any effects from arthrex?

A: According to official product information, the onset of action varies based on how the drug is taken. For acute pain, absorption might be delayed by up to 4.5 hours when taken with food. When used for conditions like arthritis, patients may see some improvement within one week, but the full therapeutic benefit may take several weeks to be observed.

Q: Do you need a prescription for arthrex?

A: Yes, regulatory authorities classify oral diclofenac tablets as a prescription-only medicine (POM). This classification is based on the need for medical supervision due to the potential risks associated with the medicine, particularly concerning the cardiovascular and gastrointestinal systems.

Q: Why are there warnings about driving or operating machinery while using arthrex?

A: Warnings about driving or operating machinery are included in the official labeling because the medicine can cause certain common side effects. These reactions, such as headache and dizziness, may affect a person's ability to safely concentrate or react.

Q: What kind of research has been done on arthrex in older adults?

A: Official documents emphasize that older adults have a greater risk for serious adverse events, particularly those affecting the gastrointestinal system. Regulatory guidance notes that use should be avoided in elderly patients who have cardiovascular or kidney (renal) risk factors.

Q: Are there any known genetic factors that affect how well arthrex works?

A: Regarding population differences, official labeling has noted that differences in pharmacokinetics—the way the body handles the drug—based on race have not been identified for diclofenac tablets.

Q: How long does arthrex stay in your system after stopping use?

A: The drug's terminal half-life—the time it takes for half of the unchanged medicine to be eliminated from the body—is reported in regulatory documents to be approximately 2 hours. This figure is used by healthcare professionals to understand the drug's duration of presence in the system.

Q: Is arthrex recommended for children?

A: Studies on how the body handles the drug (pharmacokinetics) have generally not been investigated in pediatric patients (children). According to regulatory information, the use and dose of this medicine for a child is determined by a qualified healthcare professional.

Q: Does using arthrex make me more sensitive to the sun?

A: Official product information lists photosensitivity as a potential adverse effect. This means that the drug can make your skin more sensitive to sunlight and ultraviolet light.

Q: Can arthrex affect fertility or planning a pregnancy?

A: Official labeling includes a warning regarding a potential for reversible infertility. Official guidance notes that healthcare professionals may consider withdrawing the medicine in women who are experiencing difficulty conceiving.

Q: If I have kidney problems, is arthrex still an option?

A: The use of this medicine is restricted (contraindicated) for patients with severe kidney (renal) impairment or renal failure. However, for those with mild to moderate kidney issues, caution is advised and monitoring of kidney function is generally noted as advisable.

Q: Is arthrex available as a generic medicine?

A: Yes, the active ingredient, diclofenac sodium, is widely available in generic form. Generic versions are often identified by the inclusion of 'USP' (United States Pharmacopeia) in the drug's official name.

Q: I read that arthrex can cause [serious side effect]—how common is that, factually?

A: Official regulatory documents provide factual incidence data for serious gastrointestinal events like ulcers and bleeding. These events occur in approximately 1% of patients treated for 3–6 months and rise to about 2–4% of patients treated for one year.

Q: Are there any specific dietary restrictions when using arthrex?

A: Official labeling advises that the consumption of alcohol may increase the risk of gastrointestinal bleeding while using this medicine. Aside from alcohol, there are no other general, mandatory dietary restrictions explicitly listed in the regulatory documents.

Q: What happens if I accidentally take more than the recommended amount of arthrex (informational only)?

A: The official product information for healthcare professionals includes a specific section detailing the clinical management and supportive measures for accidental overdosage. This information, including potential symptoms, is reserved for licensed medical personnel.

Q: Has arthrex been recalled for any safety reasons in the past?

A: When the medicine was reclassified as prescription-only by certain regulatory authorities (due to an increased cardiovascular risk), a 'recall to pharmacy level only' was issued. This action was taken to remove the tablets from over-the-counter sale and ensure use only occurred under a prescription.

Q: Are there any requirements to be monitored by a doctor while taking arthrex?

A: Yes, for patients using the medicine long-term, official guidance states that frequent medical tests may be required. Monitoring of kidney (renal) function is specifically recommended for individuals with high blood pressure or impaired cardiac or renal function.

Q: How long does the main effect of one dose of arthrex last?

A: While the time it takes for symptom relief to fade is individualized, regulatory information states the terminal half-life of the unchanged drug is approximately 2 hours. This figure is a measure of the medicine's presence in the system.

Q: Is arthrex metabolized differently in people of different races?

A: Official product information states that no pharmacokinetic differences—meaning differences in how the drug is absorbed, distributed, metabolized, and excreted—have been identified based on race.

Q: Can arthrex be used by people who are lactose intolerant?

A: The inactive ingredients in many marketed formulations of diclofenac tablets are listed as including lactose monohydrate. Individuals with lactose intolerance may wish to note this component in the tablet formulation.

Q: Is arthrex the same kind of medicine as [similar drug name]? What's the difference?

A: Diclofenac is in the same class as other nonsteroidal anti-inflammatory drugs (NSAIDs). It is generally considered more potent than some over-the-counter NSAIDs but is associated with a higher risk of serious cardiovascular and kidney complications, a key factor in its prescription status.

Q: Does arthrex cause long-term side effects that official materials don't usually mention?

A: Official labeling documents the serious risks, such as cardiovascular thrombotic events, which may increase with the duration of use. Clinical trials of NSAIDs have been conducted for periods up to three years, and documented risks are based on these studies.

Q: Can people who have [common chronic condition] take arthrex?

A: Specific eligibility rules are detailed for individuals with chronic conditions. For instance, the drug is restricted (contraindicated) for patients with severe heart failure or aspirin-sensitive asthma. Caution is also advised for those with a history of hypertension or impaired kidney function.

Q: What is the maximum amount of time someone can safely use arthrex?

A: Official guidance is centered on using the lowest effective dose for the shortest duration possible. This is because the risk of serious side effects may increase with the length of time the medicine is used. No single maximum duration of use is specified across all different conditions it treats.

Q: Is it normal to feel a little [minor side effect] when first starting arthrex?

A: Official clinical trial data reports the most common adverse reactions, defined as occurring with an incidence greater than 2% of patients. These common reactions include abdominal pain, nausea, diarrhea, dizziness, and headache.

Q: What does the ingredient list of arthrex look like?

A: The overall composition includes the active ingredient, diclofenac, plus a list of inactive ingredients that varies by the manufacturer and tablet formulation. These commonly include microcrystalline cellulose, hypromellose, and often lactose (monohydrate), along with various coloring agents.

Q: Does arthrex have a high risk of drug interaction compared to other medicines?

A: Diclofenac has officially documented interactions with medicines such as anticoagulants and certain blood pressure medicines. Regulatory authorities have noted that its overall cardiovascular risk profile is worse than some other traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

How should arthrex be stored and disposed of?

How to Store and Dispose of Arthrex (Diclofenac) Officially

Storage and disposal requirements for Diclofenac oral tablets are defined by regulatory labeling to maintain product quality and safety.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environment Protect from moisture, excessive heat, and light. Keep from freezing.
Container Store in the original container and keep it tightly closed.

Stability and Disposal

The medicine should not be used past the expiration date printed on the package. All tablets must be secured out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired medicine must not be thrown away into household trash or down the drain. Regulatory guidance advises returning the product to a pharmacist or following local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of arthrex found in:

A-Z Index: